Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India

Share this

Dr. Reddy Launched Hervycta (biosimilar Trastuzumab) in India


  • Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer- metastatic breast cancer and metastatic gastric cancer)
  •  Marketed as 150mg and 440mg multiple dose vials
  •  As per Dr. Reddy- it has four biosimilars commercialized in India

Ref: Dr. Reddy Laboratories | Image: Dr Reddy’s

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions